STRATA Skin Sciences, Inc.

NasdaqCM:SSKN Voorraadrapport

Marktkapitalisatie: US$12.3m

STRATA Skin Sciences Toekomstige groei

Future criteriumcontroles 0/6

STRATA Skin Sciences is forecast to grow earnings and revenue by 39.7% and 7.3% per annum respectively while EPS is expected to grow by 47.8% per annum.

Belangrijke informatie

39.7%

Groei van de winst

47.8%

Groei van de winst per aandeel

Medical Equipment winstgroei17.4%
Inkomstengroei7.3%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt19 Aug 2024

Recente toekomstige groei-updates

Recent updates

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Aug 18
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

Aug 07
Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Jun 07
STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31
STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03
Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04
We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14
Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09
What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24
Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

Winst- en omzetgroeiprognoses

NasdaqCM:SSKN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202640-2N/A71
12/31/202534-6N/A32
12/31/202433-7N/A01
6/30/202433-8-3-1N/A
3/31/202433-11-4-1N/A
12/31/202333-11-6-1N/A
9/30/202335-7-6-1N/A
6/30/202336-7-60N/A
3/31/202337-6-6-1N/A
12/31/202236-6-5-1N/A
9/30/202235-6-40N/A
6/30/202233-6-31N/A
3/31/202231-3-31N/A
12/31/202130-3-22N/A
9/30/202128-2-21N/A
6/30/202126-3-21N/A
3/31/202122-6-12N/A
12/31/202023-402N/A
9/30/202025-4N/A3N/A
6/30/202027-403N/A
3/31/202031-302N/A
12/31/201932-4-12N/A
9/30/201931-302N/A
6/30/201931-323N/A
3/31/201931-313N/A
12/31/201830-413N/A
9/30/201831-924N/A
6/30/201830-2212N/A
3/31/201831-21N/A3N/A
12/31/201732-22N/A4N/A
9/30/201730-18N/A4N/A
6/30/201731-6N/A4N/A
3/31/201730-4N/A3N/A
12/31/201631-3N/A0N/A
9/30/201633-3N/A-1N/A
6/30/201633-14N/A-3N/A
3/31/201626-22N/A-5N/A
12/31/201518-28N/A-7N/A
9/30/20159-34N/A-10N/A
6/30/20151-24N/A-12N/A
3/31/20151-15N/A-14N/A
12/31/20141-16N/A-18N/A
9/30/20141-14N/A-19N/A
6/30/20141-19N/A-20N/A
3/31/20140-27N/A-20N/A
12/31/20131-26N/A-19N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: SSKN is forecast to remain unprofitable over the next 3 years.

Winst versus markt: SSKN is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: SSKN is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: SSKN's revenue (7.3% per year) is forecast to grow slower than the US market (8.9% per year).

Hoge groei-inkomsten: SSKN's revenue (7.3% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven